Beauty treatments in South Korea made with skin tissue donated by deceased U.S. donors are expected to generate $75 million in sales in 2026. The cross-border supply chain may bring tissue from places such as San Antonio to clinics in Seoul, drawing attention to the commercial links between donor organizations, processing and the beauty-services market.
Donated skin enters South Korea’s beauty market
The treatments are part of a broader expansion in South Korea’s beauty market. Unlike conventional skincare products, they use donated human skin tissue and are marketed for reducing visible signs of aging. Available information does not identify specific products, per-treatment prices or sales by brand.
The business model connects tissue donation with consumer beauty services: donors are in the United States, the tissue is processed through the supply chain, and clinics in South Korea offer treatments to consumers. The process involves cross-border transport and multiple commercial stages, but the companies involved, transaction values and revenue split have not been disclosed.
2026 sales forecast put at $75 million
Sales of the products in South Korea are forecast to reach $75 million this year. The estimate suggests the treatments have moved beyond a service offered by individual clinics and are being considered as a market at meaningful scale. But a sales forecast is not the same as company profit, and does not establish market share, growth rates or actual consumer spending. The basis and methodology for the estimate have not been made public.
For the beauty industry, the products link raw-material supply with clinic-based services. Revenue may be generated through product sales, processing and treatment services, but no participating companies have been identified. It is therefore unclear which businesses receive most of the income or how the forecast $75 million would be distributed across the supply chain.
Supply chain from U.S. donors to Seoul remains unclear
Key questions include how donor tissue is collected and processed, which organizations handle its transfer, and how clinics explain the product’s origins to consumers. San Antonio donor organizations and Seoul clinics are cited as examples of the cross-border flow, but specific donors, suppliers, transport routes and participating institutions have not been named.
Details on sourcing and handling remain relevant to consumers alongside the market forecast. The available information also does not specify the products’ regulatory classification, applicable requirements in each jurisdiction or data on treatment outcomes. The forecast for South Korean sales stands at $75 million in 2026; further supply-chain disclosures would clarify how donated U.S. skin reaches clinic services.